SARS-CoV-2 prolonged infection during advanced HIV disease evolves extensive immune escape.
Adult
Animals
Antibodies, Neutralizing
/ blood
Antibodies, Viral
/ blood
BNT162 Vaccine
/ immunology
COVID-19
/ immunology
COVID-19 Vaccines
/ immunology
Cell Line
Chlorocebus aethiops
Female
HIV Infections
/ pathology
HIV-1
/ immunology
Humans
Immune Evasion
/ immunology
Immunocompromised Host
/ immunology
Immunogenicity, Vaccine
/ immunology
Neutralization Tests
SARS-CoV-2
/ immunology
South Africa
Vaccination
Vaccine Efficacy
Vero Cells
Beta variant
Delta variant
HIV
SARS-CoV-2
advanced HIV disease
evolution
immune escape
neutralization
variants of concern
Journal
Cell host & microbe
ISSN: 1934-6069
Titre abrégé: Cell Host Microbe
Pays: United States
ID NLM: 101302316
Informations de publication
Date de publication:
09 02 2022
09 02 2022
Historique:
received:
30
09
2021
revised:
05
12
2021
accepted:
12
01
2022
pubmed:
6
2
2022
medline:
24
2
2022
entrez:
5
2
2022
Statut:
ppublish
Résumé
Characterizing SARS-CoV-2 evolution in specific geographies may help predict properties of the variants that come from these regions. We mapped neutralization of a SARS-CoV-2 strain that evolved over 6 months from ancestral virus in a person with advanced HIV disease in South Africa; this person was infected prior to emergence of the Beta and Delta variants. We longitudinally tracked the evolved virus and tested it against self-plasma and convalescent plasma from ancestral, Beta, and Delta infections. Early virus was similar to ancestral, but it evolved a multitude of mutations found in Omicron and other variants. It showed substantial but incomplete Pfizer BNT162b2 escape, weak neutralization by self-plasma, and despite pre-dating Delta, it also showed extensive escape of Delta infection-elicited neutralization. This example is consistent with the notion that SARS-CoV-2 evolving in individual immune-compromised hosts, including those with advanced HIV disease, may gain immune escape of vaccines and enhanced escape of Delta immunity, and this has implications for vaccine breakthrough and reinfections.
Identifiants
pubmed: 35120605
pii: S1931-3128(22)00041-5
doi: 10.1016/j.chom.2022.01.005
pmc: PMC8758318
pii:
doi:
Substances chimiques
Antibodies, Neutralizing
0
Antibodies, Viral
0
COVID-19 Vaccines
0
BNT162 Vaccine
N38TVC63NU
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
154-162.e5Subventions
Organisme : NIAID NIH HHS
ID : U01 AI151698
Pays : United States
Commentaires et corrections
Type : UpdateOf
Informations de copyright
Copyright © 2022 The Authors. Published by Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of interests The authors declare no competing interests.
Références
Cell. 2021 May 27;184(11):2939-2954.e9
pubmed: 33852911
mSphere. 2021 Aug 25;6(4):e0048021
pubmed: 34431691
Cell. 2021 Apr 29;184(9):2372-2383.e9
pubmed: 33743213
Cell Host Microbe. 2021 May 12;29(5):819-833.e7
pubmed: 33789084
Ann Intern Med. 2001 Jul 3;135(1):17-26
pubmed: 11434728
Clin Infect Dis. 2021 Dec 10;:
pubmed: 34893824
Nature. 2020 Dec;588(7839):682-687
pubmed: 33045718
Bioinformatics. 2009 Aug 15;25(16):2078-9
pubmed: 19505943
PLoS Pathog. 2022 Feb 8;18(2):e1010248
pubmed: 35134084
Nature. 2021 May;593(7857):142-146
pubmed: 33780970
Nature. 1995 Jan 12;373(6510):123-6
pubmed: 7816094
Clin Infect Dis. 2021 Dec 16;:
pubmed: 34915551
Nature. 2021 Apr;592(7854):438-443
pubmed: 33690265
Nat Med. 2021 Apr;27(4):622-625
pubmed: 33654292
J Gen Virol. 1986 Jul;67 ( Pt 7):1283-91
pubmed: 2425046
Cell. 2021 Apr 29;184(9):2316-2331.e15
pubmed: 33773105
Nature. 2021 Mar;591(7849):293-299
pubmed: 33494095
Science. 2020 Aug 7;369(6504):650-655
pubmed: 32571838
Cell. 2021 May 13;184(10):2605-2617.e18
pubmed: 33831372
Nature. 2021 Dec 23;:
pubmed: 35016196
Science. 2004 Jul 16;305(5682):371-6
pubmed: 15218094
J Acquir Immune Defic Syndr. 2016 Feb 1;71(2):189-95
pubmed: 26361176
Nat Commun. 2021 Nov 4;12(1):6405
pubmed: 34737266
N Engl J Med. 2021 Dec 16;385(25):2397-2399
pubmed: 34731554
Cell Host Microbe. 2021 Mar 10;29(3):463-476.e6
pubmed: 33592168
N Engl J Med. 2018 Nov 15;379(20):1915-1925
pubmed: 30428290
Nat Med. 2021 May;27(5):917-924
pubmed: 33772244
Nature. 2021 Apr;592(7855):616-622
pubmed: 33567448
Nature. 2021 Dec 23;:
pubmed: 35016199
Bioinformatics. 2019 Mar 1;35(5):871-873
pubmed: 30124794
Cell. 2021 Apr 29;184(9):2348-2361.e6
pubmed: 33730597
Cell. 2021 Apr 15;184(8):2201-2211.e7
pubmed: 33743891
Science. 2000 Jun 9;288(5472):1789-96
pubmed: 10846155
Nat Med. 2021 Jul;27(7):1205-1211
pubmed: 34002089
Nature. 2021 Dec 23;:
pubmed: 35016194
Cell. 2021 Aug 5;184(16):4220-4236.e13
pubmed: 34242578
Cell. 2022 Feb 3;185(3):457-466.e4
pubmed: 34995482
Elife. 2021 Oct 05;10:
pubmed: 34608862
Nature. 2021 Apr;592(7853):277-282
pubmed: 33545711
Emerg Infect Dis. 2007 Feb;13(2):282-6
pubmed: 17479892
Nat Commun. 2021 Jul 7;12(1):4196
pubmed: 34234131
Vaccine. 2021 Jul 22;39(32):4423-4428
pubmed: 34210573
Nature. 2021 Nov;599(7883):114-119
pubmed: 34488225
N Engl J Med. 2020 Dec 3;383(23):2291-2293
pubmed: 33176080
N Engl J Med. 2021 May 20;384(20):1885-1898
pubmed: 33725432
Nature. 2021 May;593(7857):130-135
pubmed: 33684923
Emerg Infect Dis. 2021;27(10):2720-2723
pubmed: 34296992
Cell. 2021 Apr 29;184(9):2332-2347.e16
pubmed: 33761326